Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence
About the Study
NOTE: This study is no longer recruiting people.
Researchers are studying the affects of this breast cancer vaccine on the immune system in the following groups:
- Treatment arms:
- people diagnosed with stage 2 or stage 3 triple-negative breast cancer who have completed treatment and are considered at high risk for recurrence.
- people diagnosed with stage 2 or stage 3 triple-negative breast cancer who have completed chemotherapy and radiation and are currently receiving Keytruda (pembrolizumab).
- Prevention arm:
- people with an inherited mutation in BRCA1, BRCA2, or PALB2, who have not been diagnosed with cancer, and who are planning to undergo a risk-reducing mastectomy.
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is Not Open To:
NOTE: This study is no longer recruiting people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.